首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1800168

肝炎診斷與治療市場：2025 年至 2030 年預測

Hepatitis Diagnostic and Treatment Market - Forecasts fom 2025 to 2030

出版日期: 2025年08月14日 | 出版商:

Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

肝炎診斷和治療市場預計將從 2025 年的 332.24 億美元成長到 2030 年的 399.15 億美元，複合年成長率為 3.74%。

全球肝炎診斷和治療市場正在經歷顯著成長，這主要得益於肝炎感染率的上升，尤其是B型肝炎和C肝，這兩種病毒是造成肝炎相關死亡的主要原因。肝炎的特徵是肝臟炎症，由甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎和庚型肝炎病毒引起，其中乙型肝炎和丙型肝炎由於其慢性特性最為常見。推動市場擴張的關鍵因素包括酒精和藥物消費量的增加、肝炎藥物可及性的改善以及診斷和治療技術的進步。在全球加強肝炎醫療服務的努力的支持下，預計到2030年，市場將實現強勁成長。

市場區隔分析

按類型

市場細分為診斷和治療方法。診斷包括血液檢測、DNA/RNA檢測、切片檢查和超音波，這些對於早期發現和疾病管理至關重要。治療方法包括用於治療慢性B型肝炎和C型肝炎的抗病毒藥物和注射α干擾素，以及用於治療重症患者的肝臟移植。由於對準確且便捷的檢測的需求，診斷行業正在成長，而抗病毒療法的進步正在推動治療行業的發展。

依疾病類型

市場細分為甲型肝炎、B型肝炎、丙型肝炎及其他類型（丁型、戊型和庚型）。乙型肝炎和丙型肝炎由於其高發病率和慢性影響，在全球市場中佔據了相當大的佔有率，尤其是在醫療保健資源匱乏的地區。乙型肝炎和丙型肝炎需要長期管理，這推動了對先進治療的需求。

按地區

北美巨大的市場佔有率歸功於其先進的醫療基礎設施、廣泛的新藥獲取管道以及公眾對肝炎日益成長的認知。亞太地區預計將快速成長，這得益於醫療保健可近性的改善以及乙肝和丙肝的高負擔，尤其是在中國和東亞等肝炎流行地區。歐洲、中東和非洲以及南美也因各地區為應對各種疾病流行和治療需求做出了貢獻。

競爭格局

肝炎診斷和治療市場競爭激烈，全球主要參與者包括諾華公司、羅氏公司、默克公司、福泰製藥公司、百時美施貴寶公司、葛蘭素史克公司、吉利德科學公司、拜耳公司、艾伯維公司和楊森製藥公司。為了鞏固市場地位，這些公司正在擴大地域覆蓋範圍，並專注於創新新治療方法，例如下一代抗病毒藥物和診斷工具。策略聯盟和研發投入是滿足未滿足需求和監管要求的關鍵。

市場展望

預計到2030年，肝炎診斷和治療市場將經歷顯著成長，這得益於盛行率的上升、藥物可及性的改善以及治療創新。北美的主導地位和亞太地區的快速擴張凸顯了巨大的機遇，而高昂的治療費用等挑戰正透過全球健康舉措得到解決。市場發展軌跡凸顯了其在全球對抗慢性病毒性肝炎中的重要角色。

本報告的主要優點

深刻分析：獲得涵蓋主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他細分市場。
競爭格局：了解主要企業採用的策略策略，並了解正確策略的市場滲透潛力。
市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
可行的建議：利用洞察力來提供策略決策，在動態環境中開闢新的業務流和收益。
受眾廣泛：對於新興企業、研究機構、顧問、中小企業和大型企業來說，都是有益且具有成本效益的。

它有什麼用途？

產業和市場考量、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範與影響、新產品開發、競爭影響

調查範圍

2020 年至 2024 年的歷史數據和 2025 年至 2030 年的預測數據
成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
競爭定位、策略和市場佔有率分析
收益成長和預測細分市場和區域分析（包括國家）
公司概況（尤其是趨勢）、財務資訊和關鍵發展

The global hepatitis diagnostic and treatment market is experiencing significant growth, driven by the rising prevalence of hepatitis infections, particularly hepatitis B and C, which account for the majority of hepatitis-related mortality. Hepatitis, characterized by liver inflammation, is caused by viruses A, B, C, D, E, and G, with B and C being the most prevalent due to their chronic nature. Key factors fueling market expansion include increasing alcohol and drug consumption, improved access to hepatitis medications, and ongoing advancements in diagnostic and treatment methodologies. The market is poised for robust growth through 2030, supported by global efforts to enhance hepatitis care delivery.

Market Segmentation Analysis

By Type

The market is segmented into diagnostics and treatment. Diagnostic methods include blood tests, DNA and RNA testing, liver biopsies, and ultrasounds, which are critical for early detection and disease management. Treatments range from antiviral medications and injectable alpha interferons for chronic hepatitis B and C to liver transplants in severe cases. The diagnostic segment is growing due to the need for precise and accessible testing, while advancements in antiviral therapies drive the treatment segment.

By Disease Type

The market is categorized into Hepatitis A, B, C, and others (D, E, G). Hepatitis B and C dominate due to their high global prevalence and chronic impact, particularly in regions with limited healthcare access. Hepatitis A, while significant, is less chronic and often preventable, whereas B and C require long-term management, fueling demand for advanced treatments.

By Geography

North America holds a significant market share, attributed to its advanced healthcare infrastructure, widespread access to novel medications, and growing public awareness of hepatitis. The Asia-Pacific region is expected to witness rapid growth, driven by a high burden of hepatitis B and C, particularly in endemic areas like China and eastern Asia, alongside improving healthcare access. Europe, the Middle East, Africa, and South America also contribute, with regional efforts to address varying disease prevalence and treatment needs.

Competitive Landscape

The hepatitis diagnostic and treatment market is highly competitive, featuring major global players such as Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences, Inc., Bayer AG, AbbVie Inc., and Janssen Pharmaceuticals, Inc. These companies are focusing on expanding their geographic reach and innovating new treatments, such as next-generation antivirals and diagnostic tools, to strengthen their market positions. Strategic collaborations and R&D investments are key to addressing unmet needs and regulatory requirements.

Market Outlook

The hepatitis diagnostic and treatment market is set for substantial growth through 2030, driven by rising disease prevalence, improved drug access, and treatment innovations. North America's dominance and Asia-Pacific's rapid expansion highlight significant opportunities, while challenges like high treatment costs are being addressed through global health initiatives. The market's trajectory underscores its critical role in combating chronic viral hepatitis worldwide.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2020 to 2024 & forecast data from 2025 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

The hepatitis diagnostic and treatment market has been analyzed through the following segments:

By Type

Blood Test
DNA Test
Liver Biopsy
RNA Testing
Liver Ultrasound
Treatment
Drugs
Injectable alpha Interferons
Liver Transplant

By Disease Type

Hepatitis A
Hepatitis B
Hepatitis C
Others

By Geography

North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY TYPE

5.1. Introduction
5.2. Blood Test
5.3. DNA Test
5.4. Liver Biopsy
5.5. RNA Testing
5.6. Liver Ultrasound

6. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY TREATMENT

6.1. Introduction
6.2. Drugs
6.3. Injectable alpha Interferons
6.4. Liver Transplant

7. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY DISEASE TYPE

7.1. Introduction
7.2. Hepatitis A
7.3. Hepatitis B
7.4. Hepatitis C
7.5. Others

8. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others